# Atara Biotherapeutics, Inc.: overview ATRA · Nasdaq · CIK 1604464 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/atra.md) · [Financials](/companies/atra/financials.md) · [Filings](/companies/atra/filings.md) · [Insiders](/companies/atra/insiders.md) Latest reported revenue: [$630.0k](/filings/0001193125-26-346885.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-346885). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [40.2](/filings/0001193125-25-276219.md) | [32.8 d](/filings/0001193125-26-108361.md) | [98.1](/filings/0001193125-26-219482.md) | [17.6](/filings/0001193125-26-346885.md) | [3.5](/filings/0001193125-25-276219.md) | [1.6 d](/filings/0001193125-26-108361.md) | [0.5](/filings/0001193125-26-219482.md) | [0.6](/filings/0001193125-26-346885.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(54.1%)](/filings/0001193125-25-276219.md) | [(37.3%) d](/filings/0001193125-26-108361.md) | [39.5%](/filings/0001193125-26-219482.md) | [18.2%](/filings/0001193125-26-346885.md) | [(103.5%)](/filings/0001193125-25-276219.md) | [(160.7%) d](/filings/0001193125-26-108361.md) | [(652.9%)](/filings/0001193125-26-219482.md) | [(749.2%)](/filings/0001193125-26-346885.md) | | Net margin | % | [(54.5%)](/filings/0001193125-25-276219.md) | [(38.8%) d](/filings/0001193125-26-108361.md) | [38.7%](/filings/0001193125-26-346885.md) | [13.6%](/filings/0001193125-26-346885.md) | [(124.6%)](/filings/0001193125-25-276219.md) | [(213.5%) d](/filings/0001193125-26-108361.md) | [(803.3%)](/filings/0001193125-26-346885.md) | [(767.3%)](/filings/0001193125-26-346885.md) | | Diluted EPS | $ per share | [(2.93)](/filings/0001193125-25-276219.md) | not reported | [3.50](/filings/0001193125-26-219482.md) | [0.19](/filings/0001193125-26-346885.md) | [(0.32)](/filings/0001193125-25-276219.md) | not reported | [(0.29)](/filings/0001193125-26-219482.md) | [(0.32)](/filings/0001193125-26-346885.md) | | Free cash flow | $m | [(4.0) d](/filings/0001193125-25-276219.md) | [(24.6) d](/filings/0001193125-26-108361.md) | [(28.1)](/filings/0001193125-26-219482.md) | [(7.3) d](/filings/0001193125-26-346885.md) | [(9.8) d](/filings/0001193125-25-276219.md) | [(5.7) d](/filings/0001193125-26-108361.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [63.6](/filings/0000950170-24-037644.md) | [8.6](/filings/0000950170-25-035507.md) | [129](/filings/0001193125-26-108361.md) | [121](/filings/0001193125-26-108361.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(441.2%)](/filings/0000950170-24-037644.md) | [(3219.5%)](/filings/0000950170-25-035507.md) | [(64.7%)](/filings/0001193125-26-108361.md) | [29.7%](/filings/0001193125-26-108361.md) | | Net margin | % | not reported | [(359.1%)](/filings/0000950170-24-037644.md) | [(3220.9%)](/filings/0000950170-25-035507.md) | [(66.2%)](/filings/0001193125-26-108361.md) | [27.1%](/filings/0001193125-26-108361.md) | | Diluted EPS | $ per share | [(3.63)](/filings/0000950170-23-002185.md) | [(2.24)](/filings/0000950170-24-037644.md) | [(65.19)](/filings/0000950170-25-035507.md) | [(11.41)](/filings/0001193125-26-108361.md) | [2.57](/filings/0001193125-26-108361.md) | | Free cash flow | $m | [(231)](/filings/0000950170-23-002185.md) | [(275)](/filings/0000950170-24-037644.md) | [(194)](/filings/0000950170-25-035507.md) | [(69.0)](/filings/0001193125-26-108361.md) | [(50.9)](/filings/0001193125-26-108361.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atra/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $17.8m | 1,552,000 | | Added +1,452,407 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $9.8m | 850,000 | | Added +150,000 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $7.9m | 687,718 | | Added +493,454 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $5.1m | 441,701 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.8m | 247,047 | | Added +29,185 | | [MACKENZIE FINANCIAL CORP](/funds/919859.md) | 2026-06-30 | $2.7m | 233,249 | | Reduced −80,371 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $969.5k | 84,455 | | Added +5,433 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $862.9k | 75,128 | | Added +8,982 | | [STALEY CAPITAL ADVISERS INC](/funds/1106565.md) | 2026-06-30 | $574.0k | 50,000 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $494.1k | 43,036 | | Added +9,415 | ## Recent filings [All 1,117 filings](/companies/atra/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 16:15 ET | [10-Q](/filings/0001193125-26-346885.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346885 | | 2026-08-12 | 16:10 ET | [8-K](/filings/0001193125-26-346857.md) | 2.02 Results of operations | 0001193125-26-346857 | | 2026-07-24 | 20:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-086728.md) | Ownership report, active investor, amended | 0001104659-26-086728 | | 2026-06-26 | 16:15 ET | [8-K](/filings/0001193125-26-285498.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-285498 | | 2026-06-12 | 16:05 ET | [8-K](/filings/0001213900-26-068264.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001213900-26-068264 | | 2026-05-14 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-061506.md) | Ownership report, active investor, amended | 0001104659-26-061506 | | 2026-05-12 | 16:15 ET | [10-Q](/filings/0001193125-26-219482.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219482 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001193125-26-219420.md) | 9.01 Financial statements and exhibits | 0001193125-26-219420 | | 2026-05-11 | 18:49 ET | [SCHEDULE 13D/A](/filings/0001193125-26-217389.md) | Ownership report, active investor, amended | 0001193125-26-217389 | | 2026-05-07 | 08:10 ET | [8-K](/filings/0001193125-26-210413.md) | 8.01 Other events | 0001193125-26-210413 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108361.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f3081d5a-df3c-4fc0-81fc-99d0bed369ab) ## About the filer - CIK: 1604464 - Tickers: ATRA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.